Key Points
- Insider sale: Orlov Nicole Schaeffer sold 87,290 Insmed shares on January 2 at an average price of $175.20 for a total of $15,293,208, cutting her holding by 67.64% to 41,754 shares.
- Mixed financials: Insmed beat revenue ($142.34M vs. $114.33M est., +52.4% YoY) but missed EPS (‑$1.75 vs. ‑$1.35 est.) and continues to report large negative margins and negative ROE.
- Market view and ownership: Several institutions (RBC, Woodline, UBS, etc.) have increased stakes, and analysts hold a consensus "Moderate Buy" with an average target of $205.05 while the stock trades in a 12‑month range of $60.40–$212.75.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) insider Orlov Nicole Schaeffer sold 87,290 shares of Insmed stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the sale, the insider owned 41,754 shares of the company's stock, valued at approximately $7,315,300.80. This represents a 67.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Insmed Price Performance
NASDAQ:INSM opened at $175.07 on Wednesday. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75. The firm has a market cap of $37.34 billion, a price-to-earnings ratio of -28.28 and a beta of 1.08. The company's 50-day moving average is $190.61 and its two-hundred day moving average is $151.06. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.
Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business's quarterly revenue was up 52.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.27) EPS. Research analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.
Hedge Funds Weigh In On Insmed
A number of large investors have recently modified their holdings of the company. Royal Bank of Canada lifted its stake in shares of Insmed by 33.2% in the 1st quarter. Royal Bank of Canada now owns 245,262 shares of the biopharmaceutical company's stock valued at $18,710,000 after purchasing an additional 61,190 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Insmed by 4.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 109,489 shares of the biopharmaceutical company's stock valued at $8,364,000 after buying an additional 4,176 shares during the period. Caxton Associates LLP acquired a new position in Insmed during the first quarter valued at approximately $441,000. Woodline Partners LP lifted its position in Insmed by 53.3% during the first quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company's stock valued at $18,979,000 after buying an additional 86,540 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Insmed by 10.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company's stock worth $41,157,000 after buying an additional 52,637 shares during the period.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on INSM. Redburn Partners set a $263.00 price objective on Insmed in a report on Thursday, December 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Insmed in a research note on Wednesday, October 8th. Mizuho set a $212.00 price target on Insmed in a report on Thursday, December 18th. Cantor Fitzgerald increased their price objective on shares of Insmed from $216.00 to $230.00 and gave the stock an "overweight" rating in a report on Tuesday, December 16th. Finally, Leerink Partners reissued an "outperform" rating on shares of Insmed in a research report on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $205.05.
Check Out Our Latest Analysis on INSM
Insmed Company Profile
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
